Title: Eradication of Helicobacter pylori that contributes to hepatogenic ulcer is beneficial to
the healing of hepatogenic ulcer
Version: 1 Date: 06 Feb 2024
Reviewer's report:
The research on hepatic ulcer has not been extensively studied in recent years, and there is
inconsistency in the conclusions regarding its correlation with Hp infection. This study aims
to further explore the relationship between hepatic ulcer and Hp infection through two parts,
which has a certain extentclinical implications. 
1.It is unclear if both parts of the study were prospective studies, and if the patients of the second
part come from the first.
2.The pre-registration time for the second part of the study (ChiCTR2200061355) was in June
2022, while the patient enrollment time indicated in the study was from January 2010 to
December 2019. If the subjects in the second part of the study were derived from the patients
in the first part, there is a discrepancy in the timeline. Additionally, why did the study use
the standard triple therapy instead of the preferred bismuth-based quadruple therapy for Hp
eradication in 2022.
3.It is recommended to clearly list the inclusion and exclusion criteria.
4.If the C-UBT cessation period one month for bismuth rather than NSAIDs.
5.The study indicates that there should be 64 cases according to an 80% Hp positive rate, but
the final inclusion was only 60 cases. It is suggested to provide additional explanations for this
discrepancy.
6.The study results suggest a higher proportion of Hp infection in patients with mild esophageal
varices compared to moderate and severe cases. It is recommended to provide the clinical
significance and possible explanations for this finding.
Title: Eradication of Helicobacter pylori that contributes to hepatogenic ulcer is beneficial to
the healing of hepatogenic ulcer
Version: 1 Date: 06 Feb 2024
Reviewer's report:
The research on hepatic ulcer has not been extensively studied in recent years, and there is
inconsistency in the conclusions regarding its correlation with Hp infection. This study aims
to further explore the relationship between hepatic ulcer and Hp infection through two parts,
which has a certain extentclinical implications. 
1.It is unclear if both parts of the study were prospective studies, and if the patients of the second
part come from the first.
2.The pre-registration time for the second part of the study (ChiCTR2200061355) was in June
2022, while the patient enrollment time indicated in the study was from January 2010 to
December 2019. If the subjects in the second part of the study were derived from the patients
in the first part, there is a discrepancy in the timeline. Additionally, why did the study use
the standard triple therapy instead of the preferred bismuth-based quadruple therapy for Hp
eradication in 2022.
3.It is recommended to clearly list the inclusion and exclusion criteria.
4.If the C-UBT cessation period one month for bismuth rather than NSAIDs.
5.The study indicates that there should be 64 cases according to an 80% Hp positive rate, but
the final inclusion was only 60 cases. It is suggested to provide additional explanations for this
discrepancy.
6.The study results suggest a higher proportion of Hp infection in patients with mild esophageal
varices compared to moderate and severe cases. It is recommended to provide the clinical
significance and possible explanations for this finding.
Please review this paper.
user
Title: Eradication of Helicobacter pylori that contributes to hepatogenic ulcer is beneficial to
the healing of hepatogenic ulcer
Version: 1 Date: 06 Feb 2024
Reviewer's report:
The research on hepatic ulcer has not been extensively studied in recent years, and there is
inconsistency in the conclusions regarding its correlation with Hp infection. This study aims
to further explore the relationship between hepatic ulcer and Hp infection through two parts,
which has a certain extentclinical implications. 
1.It is unclear if both parts of the study were prospective studies, and if the patients of the second
part come from the first.
2.The pre-registration time for the second part of the study (ChiCTR2200061355) was in June
2022, while the patient enrollment time indicated in the study was from January 2010 to
December 2019. If the subjects in the second part of the study were derived from the patients
in the first part, there is a discrepancy in the timeline. Additionally, why did the study use
the standard triple therapy instead of the preferred bismuth-based quadruple therapy for Hp
eradication in 2022.
3.It is recommended to clearly list the inclusion and exclusion criteria.
4.If the C-UBT cessation period one month for bismuth rather than NSAIDs.
5.The study indicates that there should be 64 cases according to an 80% Hp positive rate, but
the final inclusion was only 60 cases. It is suggested to provide additional explanations for this
discrepancy.
6.The study results suggest a higher proportion of Hp infection in patients with mild esophageal
varices compared to moderate and severe cases. It is recommended to provide the clinical
significance and possible explanations for this finding.
assistant